Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 May 2018 Photo Supplied
Gosego Moroka recipient of the 2017 Abe Bailey Travel Bursary
Gosego Moroka, recipient of the 2017 Abe Bailey Travel Bursary.

Gosego Moroka, who employs an epitome of un-conventionalism towards his preferred tastes in life, represented the University of the Free State (UFS) on the Abe Bailey Travel Bursary tour in the UK in December 2017. He, alongside 16 other candidates from various tertiary institutions in South Africa, took heed of this opportunity of a lifetime.

The Abe Bailey Trust is a prestigious bursary awarded to young South Africans that focuses on leadership development. Trustees award bursaries to persons with a strong academic record who have shown exceptional qualities of leadership and service to their designated tertiary institutions. “I am someone who is ultracompetitive, and I always look to improve and challenge myself,” said final-year LLB Law student and 2017 UFS-Abe Bailey candidate, Gosego.

Gosego has represented the UFS in Amsterdam, in collaboration with the F1 Leadership for Change programme. He also formed part of the Global Leadership Summit, the University Scholars Leadership Symposium at the United Nations in Bangkok, Thailand, and served as the Community Service Director for the Golden Key – UFS Chapter, and developed and led the Mandela Day Community Service Project. 

Gosego’s tour with fellow bursary holders kicked off in Cape Town, where they visited Robben Island. They then travelled to Ethiopia, and visited the African Union, which he described as “state of the art.” Their next destination saw them in London where he visited the Houses of Parliament, as well as Westminster Abbey. Gosego attended plays including Matilda, and The Lion King, which he deemed culturally significant. The city of Bath, however, stood out as the highlight of his trip. He described it as the most exquisite place on earth. Stratford-upon-Avon, Shakespeare’s birthplace was also on their list of adventures. The group then travelled to Scotland where they toured Edinburgh, which Gosego described as one of the coldest places he had ever visited.

Gosego encourages students to be as genuine as possible when applying for the award. He also added that a big part of success as an individual results from who you surround yourself with. He further urges aspiring ‘Abes’ to mix with people who affirm their dreams.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept